Patents by Inventor Roger D. Tung

Roger D. Tung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20150119407
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Inventors: Roger D. Tung, Pandya Bhaumik, Scott L. Harbeson
  • Deuterated Rigosertib
    Publication number: 20150094276
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventor: Roger D. Tung
  • Deuterium-substituted xanthine derivatives and methods of use
    Patent number: 8987442
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: March 24, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Substituted xanthine derivatives
    Patent number: 8952016
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. The compound of the invention are represented by one of the following structural formulas: The variables for these structural formulas are described herein. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: February 10, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Inhibitors of Cholesterol Ester Transfer Protein
    Publication number: 20150011595
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Application
    Filed: May 6, 2014
    Publication date: January 8, 2015
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20140343119
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 20, 2014
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • 4-hydroxybutyric acid analogs
    Patent number: 8759394
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 24, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20140142179
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: June 10, 2013
    Publication date: May 22, 2014
    Inventor: Roger D. Tung
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20140121226
    Abstract: This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R1, R2, R3, R4, R5, Y1 and Y2 are described herein.
    Type: Application
    Filed: July 24, 2013
    Publication date: May 1, 2014
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • PYRAZINOISOQUINOLINE COMPOUNDS
    Publication number: 20140107127
    Abstract: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by ad ministering an antihelminthic agent, such as praziquantel.
    Type: Application
    Filed: September 18, 2013
    Publication date: April 17, 2014
    Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
  • DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES
    Publication number: 20140018390
    Abstract: The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
    Type: Application
    Filed: May 24, 2013
    Publication date: January 16, 2014
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventor: Roger D. Tung
  • Derivatives of dimethylcurcumin
    Patent number: 8575221
    Abstract: The invention relates to compounds of Formula I or Ia as disclosed herein: or pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 5, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Craig E. Masse, Roger D. Tung
  • 4-hydroxybutyric acid analogs
    Patent number: 8461197
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: June 11, 2013
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Fluorinated diaryl urea derivatives
    Patent number: 8410082
    Abstract: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 2, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Roger D. Tung, Scott L. Harbeson
  • Aminoquinoline Derivatives
    Publication number: 20130053333
    Abstract: This invention relates to novel aminoquinoline derivatives of Formula (I) or Ia, or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an aminoquinoline derivative, such as a derivative of primaquine.
    Type: Application
    Filed: January 19, 2011
    Publication date: February 28, 2013
    Inventor: Roger D. Tung
  • AZAPEPTIDE DERIVATIVES
    Publication number: 20130041156
    Abstract: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 14, 2013
    Inventors: Scott L. Harbeson, Roger D. Tung
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20130012565
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: February 14, 2012
    Publication date: January 10, 2013
    Applicant: Concert Pharmaceuticals Inc.
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20130012430
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 10, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • SUBSTITUTED DERIVATIVES OF BICYCLIC [4.3.0] HETEROARYL COMPOUNDS
    Publication number: 20120295925
    Abstract: This invention relates to novel compounds of the Formula A, B, or C, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier.
    Type: Application
    Filed: September 1, 2010
    Publication date: November 22, 2012
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Roger D. Tung, Craig E. Masse
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 8314141
    Abstract: The present invention relates to Formula (II) compounds having the structure as well as to their use in methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: November 20, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer